![From Our Perspective](https://public4.pagefreezer.com:443/content/FDA/22-02-2023T10:21/https://www.fda.gov/files/styles/medium_3/public/From%20Our%20Perspective.png?itok=E0ks8BZ-)
Recent actions highlight FDA’s effort to prevent opioid overdose deaths
Feb 2 - Agency’s focus is on expanding the availability of and access to naloxone
Feb 2 - Agency’s focus is on expanding the availability of and access to naloxone
Feb 2 - Will focus on continuous manufacturing, viral safety evaluation and more
Jan 31 - Details research activities around generic drug development
Jan 25 - Will review guidance for the inclusion of neonates in drug development
Jan 12 - Experts discuss BsUFA III goals and biosimilar regulatory science program
Jan 11 - First short-acting inhaler to contain a corticosteroid
PSAs inform consumers about the safe use and disposal of FDA-regulated products
The agency and HHS are working together to address the public health emergency
New initiative supports delivery of treatments for patients with a rare disease
Your source for the latest drug information.
Know the moment it happens.